Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
In patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab was associated with significantly longer progression-free and overall survival...